Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent

16 Nov 2023

Abstract excerpt

Glioblastoma multiforme (GBM) is the most aggressive and lethal primary brain tumor whose median survival is less than 15 months. The current treatment regimen comprising surgical resectioning, chemotherapy with Temozolomide (TMZ), and adjuvant radiotherapy does not achieve total patient cure. Stem cells' presence and GBM tumor heterogeneity increase their resistance to TMZ, hence the poor overall survival of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Glioma Diagnosis and Treatment
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38003585
DOI: 10.3390/ijms242216396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic AgentPMID 38003585Read ↗

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatmentSemantic proximity Read ↗

Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture modelsSemantic proximity Read ↗

Survival kinase genes present prognostic significance in glioblastomaSemantic proximity Read ↗

CDK12/CDK13 inhibition disrupts a transcriptional program critical for glioblastoma survivalSemantic proximity Read ↗

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivoSemantic proximity Read ↗

Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experimentsSemantic proximity Read ↗

Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of gliomaSemantic proximity Read ↗

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulationSemantic proximity Read ↗

BIRC3 is a novel driver of therapeutic resistance in GlioblastomaSemantic proximity Read ↗

CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer TherapySemantic proximity Read ↗

Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)Semantic proximity Read ↗

Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.